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Background: Traditional approaches to pharmacovigilance center on the signal detection from sponta-
neous reports, e.g., the U.S. Food and Drug Administration (FDA) adverse event reporting system
(FAERS). In order to enrich the scientific evidence and enhance the detection of emerging adverse drug
events that can lead to unintended harmful outcomes, pharmacovigilance activities need to evolve to
encompass novel complementary data streams, for example the biomedical literature available through
MEDLINE.
Objectives: (1) To review how the characteristics of MEDLINE indexing influence the identification of
adverse drug events (ADEs); (2) to leverage this knowledge to inform the design of a system for extracting
ADEs from MEDLINE indexing; and (3) to assess the specific contribution of some characteristics of
MEDLINE indexing to the performance of this system.
Methods: We analyze the characteristics of MEDLINE indexing. We integrate three specific characteristics
into the design of a system for extracting ADEs from MEDLINE indexing. We experimentally assess the
specific contribution of these characteristics over a baseline system based on co-occurrence between
drug descriptors qualified by adverse effects and disease descriptors qualified by chemically induced.
Results: Our system extracted 405,300 ADEs from 366,120 MEDLINE articles. The baseline system
accounts for 297,093 ADEs (73%). 85,318 ADEs (21%) can be extracted only after integrating specific
pre-coordinated MeSH descriptors and additional qualifiers. 22,889 ADEs (6%) can be extracted only after
considering indirect links between the drug of interest and the descriptor that bears the ADE context.
Conclusions: In this paper, we demonstrate significant improvement over a baseline approach to
identifying ADEs from MEDLINE indexing, which mitigates some of the inherent limitations of
MEDLINE indexing for pharmacovigilance. ADEs extracted from MEDLINE indexing are complementary
to, not a replacement for, other sources.
Published by Elsevier Inc.1. Introduction
The timely identification of adverse drug events (ADEs) during
the post-approval phase is an important goal of the public health
system. Undetected ADEs result in potentially preventable harm
to a substantial number of patients and impose a significant
burden on the healthcare system [1–4].While the U.S. Food and Drug Administration (FDA) collects and
analyzes drug safety reports through the FDA Adverse Event
Reporting System (FAERS) [5], the systematic inventory and collec-
tion of ADEs in structured form remains a challenge. Moreover,
given well-recognized limitations with such systems [6], pharma-
covigilance activities must evolve to encompass novel complemen-
tary data streams, in order to enrich the scientific evidence and
enhance the detection of emerging adverse drug events that can
lead to unintended harmful outcomes (e.g., [7–9]).
Text mining techniques have been used to extract ADEs from
various sources [10]. Several recent and ongoing projects have
attempted to extract ADEs from the DailyMed structured pro-
duct labels (e.g., [11]), unstructured clinical notes, like those in
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(e.g., [15,16]), from the biomedical literature, especially MEDLINE
(e.g., [17–19]), or a combination of such sources (e.g., [20]).
The biomedical literature contains valuable information about
ADEs in the form of case reports, clinical studies, and observational
studies. This information enables drug safety evaluators to assess
potentially new ADEs, such as those identified through FAERS. In
addition, the biomedical literature may contain ADEs that are not
detectable through systems such as FAERS, because healthcare
practitioners or researchers are more enthusiastic about publishing
their ADE-related findings in scientific journals than reporting
them to systems such as FAERS. Moreover, MEDLINE is one of the
largest and most comprehensive biomedical literature databases
with a broad diversity of human, animal, and in vitro data pre-
sented in a variety of publication types. In contrast to FAERS, MED-
LINE also offers the advantage of providing scientific information
that spans the entire life cycle of a drug from early pre-market drug
development through useful market life. This makes the biomedi-
cal literature a very important source of information about ADEs.
Unlike systems such as FAERS, the new data sources that are
now being considered for ADE detection, such as the biomedical
literature, were not created specifically for ADE-related applica-
tions, and therefore necessitate different approaches to uncover
ADEs.
In the MEDLINE database, ADEs are not only expressed in natu-
ral language form in the title and abstract, but also in structured
form through MeSH indexing. In MEDLINE, citations are indexed
with Medical Subject Headings (MeSH) descriptors (or ‘‘main
headings”), e.g., for diseases or drugs, that are often enriched with
qualifiers (or ‘‘subheadings”) that express the specific context in
which a topic (e.g., the drug Levofloxacin) is discussed in a given
citation (e.g., adverse effects). In addition to text mining techniques,
researchers have also leveraged MEDLINE indexing for identifying
ADEs. For example, in the context of the EU-ADR project, Avillach
et al. have used co-occurring MeSH descriptors and qualifier pairs
in MEDLINE citations as the basis for identifying ADEs [21]. Typi-
cally, ADEs are identified by the co-occurrence of a drug descriptor
qualified by adverse effects and a disease descriptor qualified by
chemically induced.
However, there are complexities and limitations to extracting
ADEs from MEDLINE indexing. For example, while most ADEs are
indexed through the combination of a disease descriptor and the
chemically induced qualifier (e.g., Tendinopathy/chemically induced),
others, because they are more frequent or important, are
completely reflected by a descriptor alone (e.g., Drug-Induced Liver
Injury) and would not be found by searching the corresponding
combination (Liver Diseases/chemically induced). In practice,
detailed knowledge about the characteristics of MEDLINE indexing
is essential to complete and accurate retrieval of ADEs.
Although our approach to extracting ADEs from MEDLINE
indexing is generally similar to Avillach’s, the goals of the two
projects are different. Avillach et al. are primarily interested in
detecting known ADEs in MEDLINE, while our goal is to systemat-
ically harvest all ADEs from MEDLINE, already known or not, in
order to support signal detection in pharmacovigilance. Therefore,
our strategy for identifying ADEs tends to be more aggressive
and goes beyond the simple co-occurrence of descriptor-qualifier
pairs pioneered by Avillach. In a pilot study designed to
expand the scope of resources beyond FAERS, we assessed the
feasibility of detecting drug-adverse event safety signals for fluoro-
quinolones through quantitative data mining of MEDLINE indexing
terms [22].
The objectives of this work are (1) to review how the character-
istics of MEDLINE indexing influence the identification of ADEs; (2)
to leverage this knowledge to inform the design of a system for
extracting ADEs from MEDLINE indexing; and (3) to assess thespecific contribution of some characteristics of MEDLINE indexing
to the performance of this system.
2. Background
In this section, we review some of the characteristics of MED-
LINE indexing and analyze their influence on the identification of
ADEs from MEDLINE indexing. In the course of our research, we
have identified nine of these characteristics as potential issues,
and have discussed them with MEDLINE indexing specialists at
the National Library of Medicine (NLM). The list of these issues is
provided in Table 1. Each issue is presented in detail later in this
section. We have developed mitigation strategies for three of these
issues (1–3), which we have integrated in the design of our system
for identifying ADEs from MEDLINE indexing. For the other issues,
we provide some recommendations in Section 5.
2.1. The chemically induced qualifier is not always necessary to denote
ADEs
As mentioned before, qualifiers are often used by MEDLINE
indexers to describe the specific aspects of a descriptor discussed
in a given article. For example, the qualifier chemically induced
can be attached to terms representing biological phenomena, dis-
eases, syndromes, congenital abnormalities, or symptoms caused
by endogenous or exogenous substances. In the context of adverse
drug events, any term with the chemically induced qualifier poten-
tially represents a drug-induced manifestation. However, also
applicable in this context are terms (predominantly) from the
Chemically-Induced Disorders (C25 subtree) in MeSH, which repre-
sent additional disorders caused by the intentional or uninten-
tional ingestion or exposure to chemical substances, such as
pharmaceutical preparations. These descriptors are ‘‘pre-
coordinated” in the sense that they implicitly denote the chemically
induced qualifier (e.g., in Drug-Induced Liver Injury), and must be
used in lieu of the corresponding descriptor-qualifier combination
(e.g., Liver Diseases/chemically induced) used for most descriptors. It
is important to note that a user searching the descriptor-qualifier
combination expressed by these descriptors would not retrieve
the corresponding citations. The corresponding ADEs would be
missed if the search was restricted to descriptors qualified by
chemically induced. Table 2 lists 19 such descriptors that can be
used for indexing ADEs.
2.2. The adverse effects qualifier is not the only qualifier to denote
ADEs
Sometimes multiple MeSH qualifiers can be logically grouped
together. For example, the related qualifiers poisoning and toxicity
are grouped under the broad qualifier adverse effects. From a
searcher’s perspective this means that all the grouped qualifiers
can be retrieved together when searching on the broad qualifier.
However, once articles are retrieved for further processing, the
exact qualifier is present in the citation. For example, a citation
retrieved from a search on Levofloxacin/adverse effectsmay actually
contain the index terms Levofloxacin/toxicity. Therefore, subse-
quent filtering of the ADE citations should consider not only
the qualifier adverse effects, but also the qualifiers it subsumes,
namely poisoning or toxicity. Along the same lines, the qualifier
contraindications also often denotes ADEs and should be considered.
2.3. The ADE context is sometimes borne by a broader term rather than
the drug of interest
As mentioned earlier, indicative of an ADE is the presence of a
drug entity with specific qualifiers (e.g., adverse effects). However,
Table 1
How the characteristics of MEDLINE indexing influence the identification of ADEs.
1 The chemically induced qualifier is not always necessary to denote ADEs
2 The adverse effects qualifier is not the only qualifier to denote ADEs
3 The ADE context is sometimes borne by a broader term rather than the
drug of interest
4 ADEs indexed with MeSH are skewed toward case reports
5 MEDLINE does not record a relation between a drug and the manifestation
of an adverse event
6 MeSH descriptors sometimes conflate several drugs
7 MEDLINE indexing rules sometimes aggregate multiple drugs under a
broader MeSH descriptor
8 Changes to MeSH have consequences on the retrieval of ADEs
9 MEDLINE indexing is not always immediately available at publication
time
“mapped to”
descriptor
“pharmacological action”
descriptor
Supplementary
Concept Record
Heading
Mapped To
Pharmacologic
Action
e.g., mivacurium
e.g., Isoquinolones/AE
e.g., Neuromuscular 
Nondepolarizing Agents/AE
(1) direct
(2) (3)
Fig. 1. Relations between supplementary concept records, descriptors, and phar-
macological actions in MeSH.
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(1), whereas many specific drugs are only represented in MeSH
as supplementary concept records (SCR), to which a qualifier can-
not be attached directly. SCRs corresponding to drugs can be linked
to qualifiers through two different mechanisms. All SCRs have a
Heading Mapped to relation to at least one descriptor in MeSH
(2). For example the SCRmivacurium has a Heading Mapped to rela-
tion to the descriptor Isoquinolines. In practice, any citation index
containing mivacurium will automatically be enriched with the
descriptor Isoquinolines. In order to qualify the drug SCR (e.g., with
adverse effects), indexers must link the qualifier to its correspond-
ing descriptor. Therefore, qualifiers added to drug descriptors in
a citation also qualify the corresponding drug SCRs in this citation.
The second possible link between a drug SCR and a qualifier is
through pharmacologic action relations. The pharmacological action
(PA) descriptors can also be qualified, similar to the Heading
Mapped to descriptors (3). For example, mivacurium might be
indexed together with its PA, Neuromuscular Nondepolarizing
Agents. In this case the qualifier of the PA descriptor also qualifies
the corresponding drug SCR.
In some cases, qualifiers denoting ADEs can be found attached
to broader descriptors, relative to the drug of interest. Leveraging
these indirect associations between a drug of interest and quali-
fiers may be important in some cases, especially when MeSH
indexing has evolved over time, resulting in the creation of more
specific descriptors (see Changes to MeSH have consequences on
the retrieval of ADEs).2.4. ADEs indexed with MeSH are skewed toward case reports
Although MEDLINE contains and indexes information from
various publication types, the majority of indexed ADE information
originates from case reports. Case reports and clinical trials have
very different foci, reflected in the indexing. While case reports
usually focus on one or a few specific ADEs for a drug (which are
indexed individually), clinical trial articles tend to report complete
safety profiles for the drug. Moreover, efficacy, not safety, is gener-
ally the main focus of clinical trials. As a result, safety information
from clinical trial articles is generally not indexed. Moreover, case
reports tend to capture rather rare and unusual ADEs, in contrast toTable 2
Pre-coordinated MeSH descriptors implicitly denoting the chemically induced qualifier.
Drug-Induced Liver Injury Drug Eruptions
Erythema Nodosum Serotonin Syndrome
Stevens–Johnson Syndrome Neuroleptic Malignant Synd
Dyskinesia, Drug-Induced Neurotoxicity Syndromes
Akathisia, Drug-Induced Anticholinergic Syndrome
Asthma, Aspirin-Induced Drug Hypersensitivity Synd
Abnormalities, Drug-Inducedclinical trials (usually not large enough to detect rare events, since
the study populations are usually sized toward efficacy). Con-
versely, it is unlikely that an overall safety profile for a drug can
be derived from case reports alone.
2.5. MEDLINE does not record a relation between a drug and the
manifestation of an adverse event
MeSH index terms for a given citation are provided as a flat list
and are generally independent of one another. In fact, in the con-
text of adverse events, it should be noted that the MEDLINE index-
ers have no way to annotate an ADE pair directly, i.e., to link a drug
and a disease for this ADE. Instead, the index will contain a drug
qualified by adverse effects and a disease term qualified by chemically
induced. Co-occurrence of the two index terms in a citation is no
guarantee for the existence of a direct link between them.
The implicit nature of these co-occurrence relationships is espe-
cially problematic when ADE articles are indexed with more than
one drug or more than one disease term. For example, a recent
study on the prevention and management of major side effects
of breast cancer drugs is indexed with the adverse events
cardiovascular, gastrointestinal, and skin diseases, as well as the
antineoplastic agents lapatinib, bevacizumab, and trastuzumab
[23]. Without further information, the simplest assumption is that
each of the drugs is possibly responsible for each of the ADEs
mentioned (cross-product).
2.6. MeSH descriptors sometimes conflate several drugs
MeSH descriptors, which are used for indexing documents in
MEDLINE, are in fact small aggregates of concepts, grouped
together as needed to support indexing and retrieval [24]. For
example, the MeSH descriptor Citalopram (D015283) is used for
indexing not only the drug citalopram (as expected), but also its
stereoisomer, the drug Escitalopram. Although Escitalopram is argu-
ably a separate drug (with specific brand names), it does not exist
in MeSH outside the descriptor Citalopram, making it impossible to
distinguish between the two drugs on the basis of the index alone.
Nowadays MeSH tends to create distinct descriptors for most
major drugs. For example, a descriptor was recently developedDrug-Induced Liver Injury, Chronic
Hand-Foot Syndrome
rome MPTP Poisoning
Psychoses, Substance-Induced
Acute Generalized Exanthematous Pustulosis
rome Chemotherapy-Induced Febrile Neutropenia
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which it was grouped prior to 2014. However, granularity
issues still exist for some drugs, such as Abatacept/Belatacept,
Dropropizine/Levodropropizine, and Sultopride/Amisulpride.
2.7. MEDLINE indexing rules sometimes aggregate multiple drugs
under a broader MeSH descriptor
Although MEDLINE indexers usually select the most specific
descriptors for the topics discussed in an article, according to the
indexing rule ‘‘Rule of Three”, a group of three or more specific
descriptors must be replaced by one more general descriptor, if
these specific terms are treed under the more general one. For
example, although an article about fluoroquinolone-associated
myasthenia gravis exacerbation [25] mentions several individual
fluoroquinolones in its abstract (levofloxacin, moxifloxacin,
ciprofloxacin, ofloxacin, gatifloxacin, norfloxacin, and trovafloxacin),
the article is not indexed with any of these drug terms but with
the more general descriptor Fluoroquinolones instead.
One consequence of the Rule of Three is that some adverse
events are captured at the class level rather than at the level of
individual drugs. This problem might be less prominent in case
reports, which focus often on fewer individual drugs than, for
instance, research and review articles.
2.8. Changes to MeSH have consequences on the retrieval of ADEs
The MeSH terminology is not static but evolves over time to
reflect changes in biomedical knowledge, as well as terminology
editorial policies. As mentioned before, MeSH descriptors some-
times group several related concepts. These groupings change over
time as part of the evolution of MeSH.
For example, MeSH treated Levofloxacin as an entry term for the
descriptor Ofloxacin, until the distinct descriptor Levofloxacin was
created in 2014. Articles indexed from 2014 onwards can be
indexed with the descriptor Levofloxacin, but earlier articles about
levofloxacin are still indexed with the descriptor Ofloxacin (see
Fig. 2). In the case of Levofloxacin, the new descriptor was actually
added retrospectively to citations previously indexed with
Ofloxacin, if the string ‘‘levofloxacin” appears in the title or abstract.
In many other cases, however, the indexing of older citations is not
modified to reflect descriptors recently added to MeSH.
While the retrospective addition of more specific index terms is
generally beneficial to retrieval, it also creates some issues. The
first issue is ambiguity. In practice, in articles such as this
review article from 2009 reporting on seizures associated with
Levofloxacin [26], it is not possible to distinguish from the indexing
between citations about levofloxacin originally indexed with
Ofloxacin, and to which Levofloxacin was later added, and citations
natively indexed with both Ofloxacin and Levofloxacin. Moreover, a
second issue arises from the fact that the qualifiers originally
attached to the broader descriptor Ofloxacin were not transferred
to the more specific descriptor Levofloxacin when it was retrospec-
tively assigned to the citation. As a consequence, in order to iden-
tify ADEs from the indexing, the adverse effects qualifier attached to
the broader descriptor Ofloxacin needs to be considered when
extracting the ADEs of Levofloxacin. (This issue was discussed
earlier under The ADE context is sometimes borne by a broader term
rather than the drug of interest).
2.9. MEDLINE indexing is not always immediately available at
publication time
Indexing MEDLINE citations with appropriate MeSH terms is
still a dominantly manual process conducted by the indexers and
the National Library of Medicine. Although articles are usuallyavailable through PubMed at the time they are provided by the
publishers (status PubMed – in process), the time for completing
the indexing (status PubMed – indexed for MEDLINE) and quality
control can vary from a few days or weeks for articles from journals
such as the Journal of the American Medical Association, New England
Journal of Medicine, Science, or Nature, to several months for articles
published in other journals. As full MEDLINE indexing cannot be
expected to be immediately available at publication time for all
submitted citations, there may be delays in identifying ADEs from
some of the most recently submitted articles.3. Materials
3.1. MEDLINE
MEDLINE is the U.S. National Library of Medicine’s (NLM) pre-
mier bibliographic database that contains currently over 23 million
references to journal articles in life sciences with a concentration
on biomedicine. MEDLINE contains citations from over 5600
worldwide journals in about 40 languages. Since 2005, between
2000 and 4000 completed references are added each day, a total
of more than 700,000 in 2013. A distinctive feature of MEDLINE
is that the records are indexed with NLMMedical Subject Headings
(MeSH) by human expert curators. Each year during November and
December, NLM makes the transition to a new year of Medical
Subject Headings (MeSH) vocabulary used to index the articles
(Year-End-Processing). In this study, we access MEDLINE through
PubMed and eUtilities, retrieving citation records in XML format
and indexed with MeSH 2014 vocabulary (as of May 2014).
3.2. Medical Subject Headings (MeSH)
TheMedical Subject Headings (MeSH) is a controlled vocabulary
produced and maintained by the NLM [27]. It is used for indexing,
cataloging, and searching the biomedical literature in the MED-
LINE/PubMed database, and other documents. As of 2014, theMeSH
thesaurus includes 27,149 descriptors organized in 16 hierarchies
(e.g., Chemicals and Drugs). Additionally, MeSH provides about
210,000 supplementary concept records (SCRs), of which many
represent chemicals and drugs (e.g., atorvastatin). Each SCR is linked
to at least one descriptor through a Heading mapped to relation
(e.g., atorvastatin is associated with Heptanoic Acids and Pyrroles).
The descriptors mapped to generally denote the chemical structure
of the drug. While most chemical descriptors provide a structural
perspective on drugs, some descriptors play a special role as
they can be used to annotate the functional characteristics of
drug descriptors and SCRs through a pharmacologic action rela-
tion (e.g., atorvastatin is linked to the mechanism of action
Hydroxymethylglutaryl-CoA Reductase Inhibitors and to the
therapeutic use Anticholesteremic Agents). MeSH 2014 is used in this
study.
3.3. RxNorm
RxNorm is a standardized nomenclature for medications pro-
duced and maintained by the U.S. National Library of Medicine
(NLM) [28]. RxNorm concepts are linked by NLM to multiple drug
identifiers for commercially available drug databases and standard
terminologies, including MeSH and ATC. RxNorm serves as a refer-
ence terminology for drugs in the U.S. The February 2014 version of
RxNorm used in this study integrates 11,788 substances, including
ingredients (IN) and precise ingredients (PIN). Ingredients gener-
ally represent base forms (e.g., atorvastatin), while precise ingredi-
ents tend to represent esters and salts (e.g., atorvastatin calcium).
RxNorm also represents clinical drugs, i.e., the drugs relevant to
Fig. 2. Changes to MeSH have consequences on the retrieval of ADEs.
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among the various drug entities are represented explicitly in
RxNorm (e.g., between ingredients and clinical drugs). NLM also
provides an application programming interface (API) for accessing
RxNorm data programmatically [29].
4. Methods and results
In this section, we present the system we have created for
extracting ADEs from MEDLINE indexing. In addition to extracting
basic co-occurrences between a drug entity, qualified by the
adverse effects qualifier, and a disease descriptor, qualified by
chemically induced, we introduce two types of refinement leverag-
ing the characteristics of MEDLINE indexing discussed in Section 2.
In the first refinement, we aim to extend the scope of descriptors
and qualifiers by adding descriptors which, in the absence of a
chemically induced qualifier, already denote adverse events
(pre-coordinated MeSH descriptors) and capturing all drug entities
bearing the ADE context qualified by adverse effects and by the
qualifiers it subsumes, namely poisoning or toxicity, as well as
contraindications. In the second major refinement, we consider
indirect links between drug entities and broader drug descriptors
bearing the ADE context, attempting to ‘‘transfer” the denotation
of ADEs to fine-grained drug entities. These two refinements are
not modular additions to the system, but rather integral to it.
However, we keep provenance information about each ADE we
extract, making it possible to analyze the specific contribution of
each part of the system. After the system design, we present an
evaluation, both quantitative and qualitative, of the specific contri-
bution of the two refinements made to the baseline system.
4.1. System design
Our approach to extracting ADEs from MEDLINE indexing can
be summarized as follows. First, we run a query against the MED-
LINE database to retrieve all articles that are relevant to adverse
drug events. In each article, we identify among the MeSH indexing
terms those that represent the drugs and diseases involved in anADE. Finally, we extract the drug-manifestation pairs, along with
provenance and metadata information (e.g., publication type).
4.1.1. Step 1: Identifying MEDLINE citations corresponding to ADEs
We designed a broad query to be run against the MEDLINE data-
base capturing all citations with at least one drug in the context of
adverse effects (drug facet) and one chemically induced manifesta-
tion (manifestation facet). The query is shown in Fig. 3.
Drug facet. The first query facet uses the query term Chemicals
and Drugs Category, which captures all citations indexed with
any drug or chemical term. The qualifier adverse effects, which
also includes the more specific qualifiers of poisoning and toxic-
ity, restricts to citations in which the drugs or chemicals are
indexed in the context of an adverse event. (Of note, PubMed
automatically extends the query to the qualifiers subsumed
by adverse effects.) This query facet also captures citations that
discuss contraindications of drugs or chemicals. Restricting to
Chemicals and Drugs Category prevents the query from capturing
irrelevant articles, e.g., articles about the adverse events of
medical devices.
Manifestation facet. The second facet of the search captures
citations indexed with at least one manifestation caused by a
drug or chemical. The qualifier chemically induced is searched
unbound to any particular manifestation term. The scope of this
facet is broadened by the addition of 19 hand-selected
pre-coordinated MeSH descriptors that implicitly denote the
chemically induced qualifier, e.g., Drug-Induced Liver Injury.
Only articles that fulfill the criteria set by both the drug and the
manifestation facets of our query are captured. For example, an
article indexed with both the descriptor/qualifier combinations
Heparin/adverse effects and Thrombosis/chemically induced would
be captured, under the assumption that it contains the ADE pair
of Heparin and Thrombosis. Similarly, an article would be captured
containing the descriptor/qualifier combination Acetaminophen/
poisoning and the pre-coordinated MeSH descriptor Drug-Induced
Liver Injury.
Fig. 3. MEDLINE search query to identify citations with adverse drug events in MEDLINE.
MT PA
SCR
Heading
Mapped To
Pharmacologic
Action
MT PA
Pharmacologic
Action
broaderbroader
Fig. 4. Relations between MESH terms representing drugs or drug classes in
MEDLINE indexing (SCR: supplementary concept record; MT: ‘‘mapped to”
descriptor; PA: ‘‘pharmacological action” descriptor).
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Utilities. The resulting list of PubMed IDs was used to retrieve
the corresponding MEDLINE records in XML format to be further
processed. The search query yielded a MEDLINE subset of 360 k
PMIDs updated through May, 2014.
4.1.2. Step 2: Identifying index terms for drugs and manifestations
involved in ADEs
In this second step, we identify index terms for drugs and man-
ifestations involved in ADEs among the MEDLINE citations
retrieved at Step 1.
4.1.2.1. Drugs. For a given citation, we consider as drug candidates
all indexed descriptors that are located in the Chemicals and Drugs
tree in MeSH as well as all supplementary concept records, if any,
that are connected to any of these descriptors through Heading
Mapped to or pharmacological action relationships. We leverage
information from the MeSH terminology to reconstruct all hierar-
chical relationships between all drug candidates for a given cita-
tion, see Fig. 4. We use the hierarchical information to report
only on terms with highest specificity, i.e., the leaf nodes in the
reconstructed tree, whereby information from qualifiers, i.e., the
active role in adverse effects, poisoning, toxicology, or contraindications,
can be passed on from higher level terms to their children. For
example, if a citation contains the SCR mivacurium, the ‘‘mapped
to” descriptor Isoquinolines, and the ‘‘pharmacological action”
descriptor Neuromuscular Nondepolarizing Agents, with relations
as depicted in Fig. 1, we identify only the SCR as the ADE drug. Fur-
thermore, this SCR ‘‘inherits” the adverse effects (AE) qualifier from
the ‘‘mapped to” descriptor and the PA descriptor, respectively, and
will be considered as an involved drug in this citation. Conversely,
if a specific drug does not bear the ADE context (directly or indi-
rectly), it is recorded as a concomitant drug.
4.1.2.2. AE manifestations. For a given citation, we consider as man-
ifestations of an adverse event all descriptors from the citation’s
index that are further qualified by the qualifier chemically induced,
as well as any of the 19 pre-coordinated descriptors from Table 2.4.1.3. Step 3: Extracting ADE pairs and metadata
In the third component of our system, we extract the ADE pairs
based on the entities identified in Step 2, filter them for clinical
relevance, and enrich the ADE pairs with metadata information.
4.1.3.1. ADE pairs. As mentioned before, ADE pairs are not explicitly
given as part of the MEDLINE indexing. Instead, we reconstruct the
pairs based on the drugs and event manifestations individually
identified in Step 2. We derive the ADE pairs for a given citation
by applying the Cartesian product between all specific drugs and
all AE manifestations. The role of a given drug in an ADE pair is
then classified as either involved or concomitant, based on the
presence or absence of the appropriate qualifiers for this drug.
4.1.3.1.1. Filtering for clinical significance. In the context of
pharmacovigilance of already approved drugs, we define as drugs
of interest those clinically relevant drugs that are currently
prescribable and available on the U.S. market. However, descrip-
tors from the Chemicals and Drugs tree (D tree) and associated
supplementary concept records (SCRs) can also denote chemicals
(e.g., carcinogens, environmental), drugs withdrawn from the
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(e.g., coffee or cosmetics), or drug-classes (e.g., pyridines). Mapping
the MeSH drugs from ADE pairs to a drug terminology helps distin-
guish drugs of interest from other entities and thus improves pre-
cision of the extraction process. RxNorm is suitable for establishing
such a filter, since it provides curated and regularly updated map-
pings to drugs in MeSH, as well as information such as prescriba-
bility and clinical relevance. Since MeSH is integrated in RxNorm,
we use the RxNorm API to map the MeSH descriptor and supple-
mentary concept record identifiers of the candidate drug entities
to RxNorm concept unique identifiers (RxCUIs). Subsequently, we
normalize all RxCUIs to Ingredients (IN), whenever mappings from
MeSH drugs were established to precise ingredients (PIN). Finally,
to assess clinical relevance of the ingredients, we require that the
ingredients be associated with at least one clinical drug (SCD) in
the RxNorm graph.
4.1.3.2. Metadata. Besides drugs and adverse events, we extract
additional information that could be relevant in the context of sig-
nal detection for pharmacovigilance. In addition to identifying
drugs as involved or concomitant, we systematically collect MeSH
terms providing information about species (B01 subtree), gender
(‘‘male” or ‘‘female”), age groups (M01.060 subtree), publication
types (V tree), epidemiologic methods (E05.318 subtree), and the
indication of a drug (any descriptor with the qualifier drug ther-
apy), whenever available. Additionally, we extract publication
dates from various data elements in the XML file of each citation.
Based on these data, we can later easily refine the analysis of our
data (e.g., restricted to ADEs found in case reports), compare differ-
ent cohorts within one set (male vs. female, studies in animals vs.
humans), or determine when information about a specific ADE was
published for the first time.
4.2. Experiments
4.2.1. Two levels of refinement over the baseline
As mentioned earlier, our approach to extracting ADEs from
MEDLINE indexing integrates two levels of refinement over the
baseline, namely an extension of the scope of descriptors and qual-
ifiers for ADEs, and the possibility for a drug descriptor to ‘‘inherit”
the ADE context (qualifier) placed on a broader drug descriptor.
The list of features corresponding to each level of refinement is
summarized in Table 3. While these refinements are already built
into our system, we measure the specific contribution of each level
by tracking at which level (Baseline, Extension, Inheritance) a given
ADE is extracted.
4.2.1.1. Baseline. This is the most restrictive of the three levels and
corresponds to a naïve approach to extracting ADEs from MEDLINE
indexing (basic co-occurrence of descriptor-qualifier pairs for
drugs and manifestations in the context of ADEs).
 The only qualifier we consider for drugs is adverse effects
[Feature 1 in Table 3]. The qualifier contraindications, as well
as the two qualifiers grouped under adverse effects, namely
poisoning and toxicity, are not considered.
 Manifestations of adverse events are only identified by descrip-
tors qualified by the chemically induced qualifier [Feature 14 in
Table 3]. The 19 pre-coordinated manifestation descriptors are
not considered.
 No indirect inheritance of the ADE context is allowed. In prac-
tice, drug descriptors are considered only if they are directly
qualified by adverse effects [Feature 9 in Table 3]; SCRs inherit
the adverse effects qualifier only from the descriptors to which
they have direct Heading Mapped to or Pharmacologic Action
relations [Features 5–6 in Table 3].4.2.1.2. Extension of the scope of descriptors and qualifiers for ADEs. In
addition to all the features of the baseline, we extend the scope of
descriptors and qualifiers for ADEs, by allowing additional
(unqualified) descriptors and additional qualifiers.
 In addition to the qualifier adverse effects, we consider the qual-
ifier contraindications, as well as the two qualifiers grouped
under adverse effects, namely poisoning and toxicity [Features
2–4 in Table 3].
 In addition to the descriptors qualified by the chemically induced
qualifier, we consider the 19 pre-coordinated manifestation
descriptors [Feature 15 in Table 3].
 As for the baseline, no indirect inheritance of the ADE context is
allowed.
4.2.1.3. Inheritance of the ADE context. At this level, we apply all the
strategies from the Baseline and Extension levels. Additionally,
inheritance of the ADE context (represented by the qualifiers
adverse effects, poisoning, toxicity, and contraindications) is allowed.
In practice, drug descriptors can inherit the ADE context from asso-
ciated ‘‘mapped to” (MT) and ‘‘pharmacological action” (PA)
descriptors [Feature 10 and 11 in Table 3]. Moreover, both drug
descriptors and SCRs can inherit the ADE context from any of their
direct or indirect parent descriptors [Feature 7, 8, 12 and 13 in
Table 3].
For example, the descriptor Levofloxacin can inherit the ADE
context from its parent descriptor Ofloxacin (Feature 10). In the
index for an article about alternatives to the drug Practolol [30],
the drug inherits the ADE context from the PA Adrenergic
beta-Antagonists, which is among the index terms for this
article, although the asserted PA in MeSH for this drug is
Adrenergic beta-1 Receptor Antagonists, a child term of Adrenergic
beta-Antagonists (Feature 13).
4.2.2. Specific contribution of each level
In the following we provide a quantitative evaluation of the
results of our system, in terms of extracted drugs, manifestations,
and ADE pairs, focusing on the specific contribution of each level.
Table 4 shows the cumulative results and the relative gain for
the three levels.
4.2.2.1. Baseline. We retrieve ADEs for 9786 unique MeSH drugs
and chemicals, of which 2146 (22%) pass our RxNorm filter for clin-
ical relevance. The relevant drugs are paired with 3007 unique
manifestations. In total we harvest 95,911 unique ADE pairs and
297,093 ADE instances from 152,729 citations.
4.2.2.2. Extension. This refinement level shows only moderate
improvement in terms of unique drugs (+93) and manifestations
(+90). However, we retrieve an additional 17,374 (+18%) unique
ADE pairs and 85,318 (+29%) ADE instances. More importantly,
45,978 of these ADE instances refer to drug-manifestation pairs
that could not be captured at the Baseline level. We harvest infor-
mation from 45,947 additional citations (+30%) that had not been
considered in our baseline approach.
4.2.2.3. Inheritance. The overall contribution of this level is mar-
ginal in comparison to the first two levels. We only retrieve 15
additional drugs and 10 additional manifestations, nonetheless
yielding 5267 additional unique ADEs and 22,889 additional ADE
instances. Again, 6262 of these ADE instances refer to drug-
manifestation pairs that could not be captured at the Baseline or
Extension levels. We harvest information from 205,597 of the
360 k citations retrieved by our broad MEDLINE query. (The
remaining 160 k MEDLINE citations may contain ADE pairs for
Table 3
Strategies followed at different levels.
Table 4
Specific contributions of each level (cumulative numbers of ADE instances and the relative gain).
Baseline +Extension +Inheritance
Number of unique drugs or chemicals 9786 14,268 (+46%) 14,712 (+3%)
Number of unique, clinically relevant drugs 2146 2239 (+4%) 2250 (+0.5%)
Number of unique manifestations 3007 3097 (+3%) 3107 (+0.3%)
Number of unique ADE pairs 95,911 113,285 (+18%) 118,552 (+5%)
Number of ADE pair instances 297,093 382,411 (+29%) 405,300 (+6%)
Number of citations 152,729 198,676 (+30%) 205,597 (+4%)
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tions, or drug classes, all of which are ignored on purpose by our
RxNorm filter).
4.2.3. Evaluation
By measuring the specific contribution of each level, we were
able to demonstrate that the two levels of refinement over the
baseline yielded significant numbers of additional ADEs, including
novel ADEs that could not be captured at previous levels. While
these additional levels are obviously productive, we need to
evaluate if the ADEs obtained at each level are valid.
In order to evaluate the quality of the ADEs extracted at the
Extension and Inheritance levels, we focus on the novel ADEs
extracted at these levels, i.e., unique ADEs that could not be
extracted at previous levels. (That is, we do not review additional
instances of ADEs already extracted at previous levels). We also
evaluate the ADEs extracted at the Baseline level. For each ADE,
we need to assess whether the MEDLINE citation from which a
given ADE is extracted provides evidence for (true positive) or
against (false positive) the ADE. We make this determination from
the information contained in the title and abstract of the MEDLINE
citation and, if necessary, from the full-text article. For this reason,
our evaluation was restricted to those ADEs for which the full-text
article was available in PubMed Central.
In practice, we randomly selected 100 ADEs for the Baseline and
Extension levels, and 50 for the less productive Inheritance level.
Two of the authors (OB and AS), physicians by training, manually
compared each candidate ADE against the information available
in the corresponding articles. Differences in opinion were dis-
cussed and the most conservative evaluation was kept in case of
disagreement.
Table 5 shows the detailed results of our evaluation. The
proportion of ADEs with supporting evidence in the article is 69%
for the Baseline level, 74% for the Extension level, and 48% for the
Inheritance level.Together with the evaluation, we also performed a failure anal-
ysis to determine the cause of the false positive ADEs. The two
most common types of error were the detection of a wrong associ-
ation and the detection of an association when there was none.
These two types of errors account for 73% of all false positive ADEs
overall. The proportion of wrong associations is higher at the Exten-
sion level (46%), while lack of association is more frequent at the
Baseline level (45%). The highest proportion of wrong associations
is observed at the Inheritance level (61%).
Wrong associations tend to occur when several drugs and/or
several manifestations are mentioned as index terms in a MEDLINE
citation. Our strategy of computing the cross-product of the drugs
and manifestations as potential ADEs may result in false positives
(e.g., if a given manifestation is related to a specific drug, but not to
all the drugs indexed in the article). For example, the drug Procar-
bazine is mentioned in the indexing of an article titled ‘‘Late cardiac
toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for
Hodgkin’s disease in adults” [31] because it is part of the MOPP
chemotherapy regimen used in the control group. While our
method rightly identifies a cardiac toxicity ADE for Doxorubicin,
Epirubicin, and Mitoxantrone, it also wrongly identifies an ADE for
Procarbazine. Lack of association primarily occurs when an article
provides evidence for the absence of an ADE, because such articles
are indexed similarly to those reporting evidence of an ADE. In fact,
in both cases, the articles discuss (potential) adverse events of
drugs, which is reflected in the indexing. For example, an article
whose conclusion is ‘‘This study supports the safety of the treat-
ment of schizophrenia with pramipexole and haloperidol as a com-
bination therapy” [32] is appropriately indexed with Pramipexole
and Dyskinesia, Drug-Induced despite the fact that the authors
demonstrate the lack of worsening of extrapyramidal side effects.
As shown in Table 5, there is a striking difference in the propor-
tion of false positive ADEs between the Baseline and Extension
levels (26–31%) on the one hand and the Inheritance level (52%)
on the other. In fact, the Inheritance level was added specifically
Table 5
Evaluation of the ADE pairs extracted at the three levels.
Level # True positive (‘‘evidence for”) # False positive
(‘‘evidence against”)
Total
Baseline 69 31 100
Extension 74 26 100
Inheritance 24 26 50
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Fig. 5. Relative and absolute contribution at different levels for random and specific
drugs.
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descriptors that had undergone recent changes (e.g., when
Levofloxacin was extracted out of the descriptor Ofloxacin, with
MEDLINE citations still showing the ADE context attached to the
previous indexing, Ofloxacin). We decided to evaluate such ADEs
specifically (15 drug descriptors with a recent mention of previous
indexing notes, such as Levofloxacin) against all other ADEs cap-
tured at this level (15 randomly selected drugs), contrasting the
number of novel ADEs specifically extracted at the Inheritance level
in each set. As shown in Fig. 5, the profiles of the two sets are com-
pletely different. For the randomly selected drugs, 82% of the ADEs
are extracted at the Baseline level, whereas 79% of the ADEs are
extracted at the Inheritance level for the 15 specifically selected
descriptors. In other words, for drugs such as Levofloxacin, most
of the ADEs would be missed if it were not for the Inheritance level.
Given that the percentage of false positive ADE is higher at the
Inheritance level, our recommendation is therefore to apply the
Inheritance level not to all drugs, but only to those MeSH descrip-
tors that have undergone recent changes and for which the ADE
context may be borne by another descriptor as a result of these
changes.5. Discussion
We outline the significance of our findings, present lessons
learned and recommendations, contrast text mining with data
mining for ADE extraction, and discuss some limitations and future
work.5.1. Significance
In this work we investigated the properties and limitations of
MEDLINE indexing for use in pharmacovigilance. We identified
nine MEDLINE indexing properties that affect the manner in which
ADEs can be identified and extracted. Based on these findings, we
proposed a comprehensive approach for the extraction of ADEs
from MEDLINE indexing.
Our evaluation reinforces the notion presented in earlier studies
that the use of MEDLINE indexing is a viable approach for extract-
ing valuable safety information from the biomedical literature. In
addition, we demonstrate that our approach provides an improve-
ment over existing methods for detecting ADEs via MEDLINE
indexing. Specifically, we demonstrate that our approach is able
to identify additional ADE-related citations and additional ADEs
with relatively high precision that would otherwise be unidentified
by existing methods. In a recent related study [33], we applied our
ADE extraction approach to evaluate MEDLINE’s capability for
signaling recently labeled adverse events. The findings of that
study provide additional support for the value of MEDLINE index-
ing for pharmacovigilance. Similarly, our pilot investigation of flu-
oroquinolone drugs also demonstrated the feasibility of using our
multi-step ADE extraction approach to generate a highly relevant,
ADE-focused subset of MEDLINE data (from a variety of publication
types) that could effectively support quantitative data mining for
the detection of drug-adverse event safety signals [22].More specifically, this investigation defines the role played by
MEDLINE indexing in support of pharmacovigilance. On the one
hand, extracting ADEs from MEDLINE indexing is relatively
straightforward, fully automated and can be repeated on a regular
basis to monitor the report of new ADEs in the biomedical litera-
ture. Moreover, the rich set of metadata attached to a MEDLINE
citation (e.g., publication date and type and population character-
istics) can easily be extracted along with the ADE and used for
fine-grained analysis of the ADE dataset. On the other hand, we
point out (and address) some of the inherent limitations of MED-
LINE indexing for pharmacovigilance and demonstrate significant
improvements over a naïve baseline approach, i.e., co-occurrence
of descriptor-qualifier pairs. We also show how the characteristics
of MEDLINE indexing contribute to biases in the ADE information
extracted from MEDLINE indexing (e.g., underreporting of some
ADE types in case reports vs. clinical trials, specific issues with cer-
tain drugs due to their representation in the MeSH vocabulary).
Understanding these limitations is critical for developing mitiga-
tion strategies when possible. At a minimum, biomedical research-
ers need to be aware of these limitations in order to define the role
ADEs from MEDLINE indexing can play in pharmacovigilance
together with other sources of information (e.g., spontaneous
reports and clinical trials). These biases and limitations are also
the reason why an evaluation against reference lists of ADEs would
not be meaningful and was not performed as part of this study.
5.2. Lessons learned and recommendations
5.2.1. From the experiment
Overall, the simple analysis of co-occurrence of descriptor-
qualifier pairs (Baseline level) remains a valid strategy for extract-
ing ADEs from MEDLINE indexing. It provides the bulk of the ADEs
extracted from MEDLINE indexing, of which 69% were shown to be
correct.
However, a significant number of important ADEs are denoted
by pre-coordinated MeSH descriptors and could not be identified
if only descriptor-qualifier pairs were used (e.g., Drug-Induced Liver
Injury). We were able to retrieve 17,374 (+18%) additional unique
ADE pairs. The quality of ADEs extracted at the Extension level is
even slightly higher (74% correct) than for the Baseline level. These
important ADEs could not have been captured at all with an
approach limited to simple descriptor-qualifier pairs. A smaller
number of ADEs are captured by qualifiers other than adverse effects.
For a small number of drugs, ADEs can be captured only by con-
sidering indirect links between a specific drug and the broader
descriptor bearing the ADE context (Inheritance level). While this
phenomenon is only marginal overall, it is very important for speci-
fic drugs (e.g., levofloxacin). However, it should not be applied across
the board, as its performance is generally limited (48% correct).
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5.2.2.1. ADEs indexed with MeSH are skewed toward case reports.
ADEs extracted from MEDLINE are not sufficient for signal detec-
tion for pharmacovigilance, as most of the ADEs indexed come
from case reports, in which the ADEs reported are not representa-
tive of all ADEs. Therefore, the integration of multiple sources of
information beyond the biomedical literature is likely to be critical
in order to obtain comprehensive drug safety information. MED-
LINE indexing should be considered as one source of ADE informa-
tion, along with spontaneous reporting (FAERS), observational data
(from electronic health records), etc.
5.2.2.2. MEDLINE does not record a relation between a drug and the
manifestation of an adverse event. The overall quality (i.e., signal-
to-noise ratio) of the data originating from peer-reviewed and
manually indexed articles should be generally higher than, for
instance, the quality of the raw data submitted to the FDA Adverse
Event Reporting System (FAERS), where consumers might report
entire medication lists alongside the list of symptoms they experi-
enced. Overall, despite potential false positives, the ADEs extracted
from MEDLINE indexing are expected to be more targeted than
those from spontaneous reporting systems.
5.2.2.3. MeSH descriptors sometimes conflate several drugs. Although
we showed this was a problem for some drugs (e.g., levofloxacin),
the impact of this characteristic of MeSH indexing is limited overall.
Moreover, over the past years, MeSH has created distinct descrip-
tors for most major drugs. However, the evolution of the MeSH
vocabulary for drugs that were once conflated into one descriptor
should be taken into account for the analysis of specific drugs.
5.2.2.4. MEDLINE indexing rules sometimes aggregate multiple drugs
under a broader MeSH descriptor. This issue is an indexing issue,
independent from the organization of the MeSH vocabulary itself.
Although we have not specifically measured its impact, we suspect
it is limited overall. Moreover, this rule applies not to specific
drugs, but to all MeSH descriptors. Therefore, it should not have
introduced any bias toward specific ADEs.
5.2.2.5. Changes to MeSH have consequences on the retrieval of
ADEs. This issue is a consequence of the evolution of the MeSH
vocabulary, especially when drugs that were conflated under the
same descriptor become distinct descriptors. As mentioned earlier,
while important for specific drugs, the impact of this issue is
marginal overall.
5.2.2.6. MEDLINE indexing is not always immediately available at
publication time. As a consequence, ADEs extracted from MEDLINE
indexing cannot be expected to be immediately available at publi-
cation time. This lag time must be taken into account when
extracting ADEs (or other information) from MEDLINE indexing.
5.3. Text mining vs. data mining for ADE extraction
It is worth noting the parallel efforts for extracting ADEs from
the biomedical literature, which apply natural language processing
(NLP) techniques to article titles and abstracts [17–19]. Given the
current state of the art, it is unclear which of the two
approaches—MEDLINE indexing versus NLP—is the better approach
for extracting ADEs. These two approaches are most likely comple-
mentary. Nonetheless, many of the advantages and limitations of
MEDLINE indexing versus NLP are apparent. The indexing is readily
available, human-curated, is based on the full text of articles (not
just abstracts), and does not require the use of complex NLP
techniques that are more prone to error. Conversely, applying NLP
to article titles and abstracts (or full-text articles when available)is not limited by the scope and granularity of the MeSH vocabulary
or by the NLM annotation rules. The use of NLP is also not limited by
time delays resulting from the need for human annotation.
5.4. Limitations and future work
5.4.1. MeSH vs. other ADE vocabularies
One limitation of this study is that it does not address the com-
parison between ADEs extracted from MEDLINE indexing (in refer-
ence to the MeSH vocabulary) and other sources of ADEs, coded to
different vocabularies. For example, the Medical Dictionary for
Regulatory Activities (MedDRA) is the terminology most com-
monly used by regulatory authorities in the pharmaceutical indus-
try and is endorsed for adverse event classification by the
International Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human Use (ICH)
[34]. Such comparison would require a mapping between MeSH
and MedDRA. While equivalences between MeSH and MedDRA
are available through the Unified Medical Language System (UMLS)
Metathesaurus, meaningful comparison between the MEDLINE and
FAERS ADEs would require a significant curation effort in order to
bridge granularity differences between the two vocabularies. This
effort was beyond the scope of this investigation, but will be the
object of future work. In addition, the hierarchical structure of
MedDRA allows for vertical aggregation of manifestation terms
up to the System Organ Class (SOC) level or horizontal aggregation
through Standardised MedDRA Queries (SMQs). MeSH only sup-
ports vertical aggregation through its hierarchical structure, and
is organized to support indexing and retrieval, not pharmacovigi-
lance. Groupings of MeSH descriptors would need to be defined
in order to meaningfully aggregate the ADEs extracted from MED-
LINE indexing.
Of note, the indexing of drugswithMeSH does not offer the same
challenges. Through the integration of MeSH drugs in RxNorm,
these drugs are already aligned with other drug classification sys-
tems, such as the Anatomical Therapeutic Chemical (ATC) classifica-
tion system developed by the World Health Organization (WHO).
ATC supports the aggregation of drugs into classes on four levels
of granularity. It is commonly used for pharmacoepidemiology
and in research projects (e.g., EU-ADR). Comparing classes between
MeSH and ATC is not as straightforward [35], and exploiting the
ADEs extracted from MEDLINE indexing at the level of drug classes
(as opposed to individual drugs) remains somewhat challenging.
5.4.2. ADE selection for signal generation
It was beyond the scope of this investigation to determine
which statistical techniques would be best for analyzing the signal
generated from MEDLINE indexing. Similarly, we chose to follow a
search and extraction strategy that retrieves a broad set of ADEs for
a diverse set of chemicals and drugs from various types of publica-
tions and studies. While Avillach filtered out some publication
types as non-contributory [21], and Gurulingappa only considered
case-reports [17], we chose to be inclusive of all publication types
and to capture provenance information, rather than making an a
priori selection. This strategy provides greater flexibility and sup-
ports refinements of the statistical analysis as needed.
6. Conclusions
To enhance the detection of emerging adverse drug events that
can lead to unintended harmful outcomes, pharmacovigilance
activities needs to evolve to encompass novel complementary data
streams, for example the biomedical literature available through
MEDLINE.
In this investigation, we focused on the extraction of ADEs
from MEDLINE indexing. We confirmed that the analysis of
R. Winnenburg et al. / Journal of Biomedical Informatics 57 (2015) 425–435 435co-occurrence of descriptor-qualifier pairs remains a valid strategy.
We proposed significant improvements over a baseline approach,
in order to mitigate some of the inherent limitations of MEDLINE
indexing for pharmacovigilance. The system we created success-
fully extracted 405,300 ADE instances from 205,597 MEDLINE
citations vs. 297,093 ADE instances from 198,676 citations for
the baseline system. We verified that the majority of these
additional ADE instances are correct.
ADEs extracted from MEDLINE indexing for pharmacovigilance
purposes are complementary to, not a replacement for, other
sources. ADEs could not be reliably extracted fromMEDLINE index-
ing if MEDLINE did not provide fine-grained indexing, not only at
the level of individual drugs and manifestations, but also reflecting
the specific ADE context for these index terms.Disclaimer
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